Chunghwa Chemical Synthesis & Biotech Co., Ltd. (TPE:1762)
34.50
-0.15 (-0.43%)
Aug 19, 2026, 1:30 PM CST
TPE:1762 Revenue
Chunghwa Chemical Synthesis & Biotech had revenue of 305.18M TWD in the quarter ending June 30, 2026, a decrease of -11.29%. This brings the company's revenue in the last twelve months to 934.29M, down -20.25% year-over-year. In the year 2025, Chunghwa Chemical Synthesis & Biotech had annual revenue of 804.88M, down -40.26%.
Revenue (ttm)
934.29M
Revenue Growth
-20.25%
P/S Ratio
2.85
Revenue / Employee
4.72M
Employees
198
Market Cap
2.67B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 804.88M | -542.50M | -40.26% |
| Dec 31, 2024 | 1.35B | -739.07M | -35.42% |
| Dec 31, 2023 | 2.09B | -30.70M | -1.45% |
| Dec 31, 2022 | 2.12B | 182.44M | 9.43% |
| Dec 31, 2021 | 1.93B | 391.11M | 25.34% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Syngen Biotech | 2.05B |
| Apex Biotechnology | 1.87B |
| HeXun Biosciences | 308.21M |
| BioGend Therapeutics | 236.58M |
| 3D Global Biotech | 159.19M |
| Shine-On BioMedical | 50.62M |
| Intech Biopharm | 48.55M |
| GlycoNex Incorporation | 36.35M |